Sixteen children with biopsy-confirmed type I membranoproliferative glomerulonephritis (MPGN) were treated with six alternate-day intravenous pulses of methylprednisolone followed by single-dose alternate-day prednisone for 12–66 months (mean 37 months). The average length of follow-up was 52 months (range 12–127 months). Compared with pretreatment values, the frequency of hematuria (13/16 vs. 8/16,P<0.05) and the levels of serum albumin (2.66 ± 0.69 vs. 3.76 ± 0.39 g/dl,P < 0.001), creatinine clearance (97 ± 37 vs. 129 ± 26 ml/ min/1.73 m2,P<0.001), and proteinuria (5.2 ± 5.1 vs. 1.0 ± 0.8 g/day, P<0.001) were significantly improved after 3 months of therapy. Improvement has persisted through the end of the follow-up period. Repeat kidney biopsies showed a significant reduction in acute changes but an increase in chronic changes. Thirteen patients have been off therapy from 1 to 74 months (mean 20.8 months). Nine have a normal urinalysis, creatinine clearance, and protein excretion. The remainder have normal renal function but proteinuria ranging from 3.2 to 4.3 g/day. The data support the evidence of other investigators that corticosteroid therapy is beneficial in type I MPGN and suggest that initiation with pulse methylprednisolone may promote early stabilization of the disease.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Nash MA, Edelmann CM Jr, Bernstein J, Barnett HL (1992) The nephrotic syndrome. In: Edelmann CM Jr (ed) Pediatric kidney disease, 2nd edn. Little Brown, Boston, pp 1247–1266
D'Amico G, Ferrario F (1992) Mesangiocapillary glomerulonephritis. J Am Soc Nephrol 2:S159-S166
Schmitt H, Bohle A, Reineke T, Mayer-Eichberger D, Vogl W (1990) Long-term prognosis of membranoproliferative glomerulonephritis type I. Nephron 55:242–250
Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, Haycock GB, Hicks J (1983) Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med 74:175–191
McEnery PT (1990) Membranoproliferative glomerulonephritis: the Cincinnati experience — cumulative renal survival from 1957 to 1989. J Pediatr 116:S109-S114
Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr (1992) Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone — a report of The International Study of Kidney Disease in Children. Pediatr Nephrol 6:123–130
Ford DM, Briscoe DM, Shanley PF, Lum GM (1992) Childhood membrano-proliferative glomerulonephritis type I: limited steroid therapy. Kidney Int 41:1606–1612
Mota-Hernandez F, Gordillo-Paniagua G, Munoz-Arizpe R, Lopez-Arriaga JA, Barboza-Madueno L (1985) Prednisone versus placebo in membrano-proliferative glomerulonephritis: long-term clinicopathological correlations. Int J Pediatr Nephrol 6:25–28
Donadio JV, Anderson CF, Mitchell JC III, Holley KE, Ilstrup DM, Fuster V, Chesebro JH (1984) Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy. N Engl J Med 310:1421–1426
Kincaid-Smith P (1972) The treatment of chronic mesangiocapillary (membranoproliferative) glomerulonephritis with impaired renal function. Med J Aust 2:587–592
Cattran DC, Cardella CJ, Roscoe JM, Charron RC, Rance PC, Ritchie SM, Corey PN (1985) Results of a controlled drug trial in membrano-proliferative glomerulonephritis. Kidney Int 27: 436–441
Zimmerman SW, Moorthy AV, Dreher WH, Friedman A, Varanasi U (1983) Prospective trial of warfarin and dipyridamole in patients with membranoproliferative glomerulonephritis. Am J Med 75: 920–927
Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E (1994) Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron 67:59–65
Andreoli SP, Yum MN, Bergstein JM (1986) IgA nephropathy in children: significance of glomerular basement membrane deposition of IgA. Am J Nephrol 6:28–33
Donadio JV Jr, Offord KP (1989) Reassessment of treatment results in membranoproliferative glomerulonephritis with emphasis on life-table analysis. Am J Kidney Dis 14:445–451
Watson AR, Poucell S ThornerP, Arbus GS, Rance CP, Baumal R (1984) Membranoproliferative glomerulonephritis type I in children: correlation of clinical features with pathologic subtypes. Am J Kidney Dis 4:141–146
Habib R, Kleinknecht C, Gubler MC, Levy M (1973) Idiopathic membranoproliferative glomerulonephritis in children. Report of 105 cases. Clin Nephrol 1:194–214
McEnery PT, McAdams AJ, West CD (1986) The effect of prednisone in a high-dose, alternate-day regimen on the natural history of idiopathic membranoproliferative glomerulonephritis. Medicine (Baltimore) 64:401–424
About this article
Cite this article
Bergstein, J.M., Andreoli, S.P. Response of type I membranoproliferative glomerulonephritis to pulse methylprednisolone and alternate-day prednisone therapy. Pediatr Nephrol 9, 268–271 (1995). https://doi.org/10.1007/BF02254181
- Membranoproliferative glomerulonephritis
- Nephrotic syndrome